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Objectives: This study was a trial to demonstrate the prophylactic effect of diclofenac, a widely
used anti-inflammatory drug (diclofenac potassium, CAS-15307-81-0, Ciba Geigy, 334.2) in
experimental schistosomiasis mansoni. Two different dose regimens were used to explore the
effects upon worm load, tissue egg load, and hepatic granuloma size.
Methods: In this study, a group of 50 Swiss albino mice was used. This group was divided into five
subgroups: subgroup I constituted infected untreated control mice; subgroup II, infected mice
given 0.5 mg diclofenac orally 24 h post infection, then sacrificed three weeks later; subgroup III,
infected mice given 0.5 mg diclofenac orally six weeks post infection and sacrificed one week
later; subgroup IV, infected mice administered 1 mg diclofenac orally 24 h post infection and
sacrificed three weeks later; and subgroup V, infectedmice given 1 mg of the drug orally six weeks
post infection and sacrificed one week later.
Results: Mice given the high dose regimen (1 mg orally/mouse) 24 h post infection, then
sacrificed three weeks later, demonstrated a significant reduction in the immature worms
recovered, compared to the untreated controls. Animals receiving the high dose of the drug
six weeks post infection, then sacrificed one week later, revealed a drop in the number of mature
worms and in the tissue egg load (hepatic and intestinal), and the smallest hepatic granuloma
measurement compared to the untreated controls. These findings were less conspicuous in
animals given the low dose regimen.
Conclusion: Diclofenac could be used successfully as a preventive agent against schistosomiasis
mansoni infection in endemic areas.
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Egypt without schistosomiasis? It sounds like a dream. The
disease continues to rank second to malaria in the world’s
parasitic diseases in terms of the extent of endemic areas and
the number of infected people. There is as yet no vaccinePublished by Elsevier Ltd. All rights reserved.
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apy with praziquantel.1 In view of concern about the devel-
opment of tolerance and/or resistance to praziquantel,2
there is a need for novel drugs for the prevention and cure
of schistosomiasis.1 Diclofenac is a commonly used anti-
inflammatory drug in gout, musculoskeletal and periarticular
disorders.3 Farag et al.4 previously tried ibuprofen or diclo-
fenac sodium in schistosomiasis mansoni. The authors found
that the drug succeeded in reducing the severity of infection
with attenuation of hepatic fibrosis, particularly when the
treatment was initiated early.
The objectives of this study were to investigate the use of
diclofenac, 0.5 and 1.0 mg, in a trial to demonstrate its
prophylactic effect upon the immature and mature stages
of experimental schistosomiasis mansoni, and also patholo-
gical parameters of assessment including hepatic granuloma
measurement in animals sacrificed seven weeks post infec-
tion. This study was performed to include the immature
worm count, mature worm load, tissue egg loads, and hepatic
granuloma size.
Material and methods
A group of 50 Swiss male albino mice of C.D. strain, weighing
18—20 g each were infected with an Egyptian strain of Schis-
tosoma mansoni cercariae. The strain used originated from
the Nile Delta in Egypt, and has been bred through mice and
Biomphalaria alexandrina for six years. Animals were sup-
plied and bred through the Schistosome Biological Supply
Program, Theodor Bilharz Research Institute, Imbaba, Cairo,
Egypt. The experimental animals were maintained for 112—
124 days in air-conditioned rooms at 21 8C and given food
with a 24% protein content. The animal experiments were
carried out according to the internationally valid guidelines
in an institution responsible for animal ethics (Theodor Bil-
harz Research Institute).5
Diclofenac (diclofenac potassium, (0-(2,6-dichloroanili-
no)phenyl)acetate, Ciba Geigy, 334.2) was supplied by the
Theodor Bilharz Research Institute. The usual human dose for
inflammatory conditions is 100 mg/day given orally in 2—3
divided doses. The 50 mice were divided equally into five
subgroups of 10: subgroup I received 80 Schistosoma mansoni
cercariae per mouse by subcutaneous injection, and served
as control infected untreated mice sacrificed three weeks
later; subgroup II constituted infected mice given 0.5 mg
diclofenac orally per mouse as a single dose 24 h post infec-
tion, and sacrificed three weeks later; subgroup III consti-
tuted infected mice treated with diclofenac orally, 0.5 mg
per mouse as a single dose six weeks post infection, andTable 1 Effect of diclofenac on the immature stages in Schistoso
sacrificed three weeks later
Animal group
Group I — infected controls
Group II — infected, given low dose regimen 0.5 mg/mouse
Group IV — infected, given high dose regimen 1.0 mg/mouse
a Statistically significant difference from infected untreated controlssacrificed one week later; subgroup IV constituted infected
mice given 1.0 mg of the drug orally per mouse as a single
dose 24 h post infecton, and sacrificed three weeks later; and
subgroup V constituted infected mice administered diclofe-
nac 1.0 mg orally as a single dose six weeks post infection,
and sacrificed one week later.
The drug was diluted in distilled water and was given
through an esophageal syringe. After the animals had been
sacrificed by cervical dislocation, perfusion was done taking
care to separate hepatic from portomesenteric worms.6
Livers were collected and fixed in 10% formalin solution
for subsequent preparation of hematoxylin and eosin-stained
sections for granuloma measurements.7
Bilharzial hepatic granulomas were measured in stained
sections by selecting lesions containing single eggs in their
centers. The mean diameter of each lesion was obtained by
measuring perpendicular diameters using an ocular micro-
meter. The volume of each lesion was calculated from its
mean diameter using the formula:
V ¼ r3  p 43
Themean volume per group represents themean of 70 lesions
and is expressed in mm3.
Statistics
Comparison was done between each treated group and the
untreated control group. The percentage change between
the two groups to be compared was assessed using the
formula:
ðmean value of the first groupmean
value of the second groupÞ
mean value of the first group
 100
Differences between the mean scores of any of the two
groups to be compared were tested for significance using an
unpaired two-tailed Student’s t-test. The data were consid-
ered significant if p values were <0.05.
Results
Immature worm count
Themean immature worm count in the control and treatment
groups, groups II and IV, as shown in Table 1 were 36.5, 21.5,
and 16.5 worms, respectively. Group IV had the lowest
immature worm count. The difference was statistically sig-
nificant from untreated control mice at p < 0.001.ma mansoni-infected mice treated one day post infection and





21.5  0.8a 41.1
16.5  0.5a 54.8
at p < 0.001.
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Table 2 Effect of diclofenac on the mature worm and tissue egg loads in Schistosoma mansoni-infected mice treated six weeks
post infection and sacrificed one week later










egg load  SE
Percentage
reduction
Group I — infected
controls
30.8  4.1 4664.2  126.3 4535.6  1212.6
Group III — infected,
given 0.5 mg/mouse
23.7  4.2 23.1 4588  1337 1.6 3183  739 29.8
Group V — infected,
given 1.0 mg/mouse
24.3  2.5 21.1 4207  1216 9.8 2787.5  927a 38.5
a Statistically significant difference from infected untreated controls at p < 0.001.
Table 3 Effect of diclofenac on the hepatic granuloma measurements in Schistosoma mansoni-infected mice treated six weeks
post infection and sacrificed one week later
Animal group Percentage mature
worm reduction
Mean hepatic granuloma
diameter in mm  SE
Percentage
reduction
Group I — infected controls 140.7  3.1
Group III — infected, given 0.5 mg/mouse 23.1 137.3  2.8 2.4
Group V — infected, given 1.0 mg/mouse 21.1 123.4  0.7a 11.8
a Statistically significant difference from infected untreated controls at p < 0.05.Mature worm load and tissue egg loads
Group V had the lowest worm and tissue (hepatic and intest-
inal) egg loads. The intestinal egg load was statistically
significantly lower than in untreated control mice at
p < 0.001 (Table 2).Figure 1 Liver section of a representative of the infected
control group of mice (8 weeks post infection), illustrating large
cellular granuloma composed of a mixture of chronic inflamma-
tory cells rich in eosinophils. The intact cellular miracidium is
seen inside the ovum. Adjacent hepatocytes show hydropic
change and focal atypical hyperplasia (H&E  200) (mean dia-
meter = 140 mm).Hepatic granuloma measurements
Group V had the smallest hepatic granuloma mean diameter
(123.4  0.7). This value, when compared with the untreated
controls, was statistically significant at p < 0.05 (Table 3,
Figures 1—3).
It was noted that animals tolerated the treatment very
well. The dose given succeeded in performing the optimal
antischistosomal activity without any undesirable side
effects.Figure 2 Liver section of a representative of the infected and
orally treated low dose diclofenac mice showing a small hepatic
fibrocellular granuloma (H&E  200) (mean diameter = 137 mm).
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Figure 3 Liver section of a representative of the infected and
orally treated high dose diclofenac mice showing a small hepatic
fibrocellular granuloma (H&E  200) (mean diameter = 123 mm).Discussion
From this study, it could be concluded that diclofenac exerts
potent prophylactic activity in experimental schistosomiasis
mansoni infection, concurrent with its anti-inflammatory
action. This is evident by the lower level of immature worms
recovered in the group given 1.0 mg of the drug 24 h post
infection and sacrificed three weeks later (group IV). The
drug also produced a deleterious effect on adult schisto-
somes, evidenced by lowered worm recovery in the group
given 1.0 mg diclofenac six weeks post infection and sacri-
ficed one week later (group V). This group also exhibited a
lowered hepatic and intestinal egg load, and the smallest
hepatic granuloma mean diameter.
Diclofenac was previously tried in experimental schisto-
somiasis mansoni by Farag et al.4 The authors postulated that
arachidonic acid metabolites participate in skin penetration
by schistosome cercariae and in the pathogenesis of schis-
tosomiasis. They treated mice with ibuprofen or diclofenac
sodium (2.5 mg/kg/day) for seven days before infection. The
authors noted a significant drop in the liver weight, worm
load, and hepatic hydroxyproline content compared to the
untreated mice. Again, if treatment was continued for two
days post infection, a significant drop in hepatic gamma-
glutamyl transpeptidase activity was noted.4 Furthermore,
when diclofenac sodium was administered in a smaller dose
of 1.2 mg/kg/day, all the measured parameters of infection
were significantly lower when the treatment was initiated
seven days post infection. Farag et al.4 concluded that
treatment with ibuprofen or diclofenac sodium was effective
in reducing the severity of infection and in attenuating
hepatic fibrosis particularly when the treatment was
initiated early.
More recently, Ojewole and Adewunmi3 found that the
fruit of Tetrapleura tetrapterawas used in African traditional
medicine for the management and/or control of an array of
human ailments such as arthritis, asthma, diabetes mellitus,
hypertension, epilepsy, and schistosomiasis. The authorstried diclofenac 100 mg/kg p.o. and chlorpropamide
250 mg/kg p.o. as reference anti-inflammatory and hypogly-
cemic agents for comparison. They found that the Tetra-
pleura tetraptera fruit produced a dose-related, significant
reduction of the fresh albumin-induced acute inflammation
of the rat hind paw edema. The plant extract also produced a
dose-dependant significant drop in the blood glucose level of
both fasted normal and fasted diabetic rats. The results
indicate that this plant extract could be used as an anti-
inflammatory and hypoglycemic agent in some communities
in West Nigeria.3
The use of anti-inflammatory or antifibrotic agents in
schistosomiasis mansoni has been previously tried by Giboda
et al.8 and Hassan et al.9 The authors suggested the use of an
antifibrotic agent, beta-aminopropionitrile (BAPN) in con-
junction with praziquantel to inhibit cross-linking of newly
deposited collagen in murine schistosomiasis mansoni, by
blocking lysyl oxidase. Mansy et al.10 reported that early
praziquantel therapy after the 8th week of infection
decreased hepatic collagen content, while later treatment
at the 18th week of infection increases hepatic collagen.
Badawy et al.11 stated that the antifibrotic agent colchicine
postpones granulomatous reaction healing and diminishes
collagen deposition rather than inhibiting collagen formation
or degradation. Recent trials with interferon alpha demon-
strated an antifibrotic effect that is independent from its
antiviral effect.12 The product can reduce and prevent
deposition of fibrotic tissue in the liver by increasing its
capacity to degrade type I and type III collagen, and by
increasing the activity of plasminogen activator. This anti-
fibrotic activity of interferon may be mediated by cytokines
that bring about histologic improvement of the liver. Gross
et al.,13 postulated that among the cytokines that appear to
orchestrate fibrogenic changes, transforming growth factor
beta (TGF beta) appears to be predominant. When the
activity of TGF beta has been altered experimentally by gene
therapy, hepatic fibrosis has been prevented or even
reversed.13
In this study, mice given the high dose diclofenac regimen
(1.0 mg/mouse) 24 h post infection, revealed a recovery of
the lowest number of immature worms. As regards previous
trials of antischistosomal drugs in different time periods prior
or post infection, Nessim et al.,5 tried the broad spectrum
anthelmintic drug flubendazole on Schistosoma mansoni-
infected mice. The authors postulated that mice given the
drug 25 days post infection revealed a significant reduction in
the recovery of adult schistosomes after portal perfusion,
and the smallest granuloma mean diameter. These data were
less notable in mice treated 4 h after and 24 h before infec-
tion. Again, in this study, the smallest hepatic granuloma
measurement was recorded in the group given diclofenac
1.0 mg/mouse six weeks post infection.
Reduction in granuloma size after treatment has previously
been reported byBotros et al.,14 concerning praziquantel. The
authors noted diminution in the number of T-helper cells in the
granulomata. Botros et al.,14 and Hassan et al.15 stated that
this reduction in granuloma size after treatment could be the
result of inhibition of the inflammatory mediators released
locally at the site of granulomatous inflammation. Moreover,
suppression of this reaction as a T-cell mediated response
cannot be ruled out. In favor of their conclusion was the
reduction in the number of Lyt1 T-lymphocytes in the granu-
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granuloma sizeafterflubendazole treatment is consistentwith
the assumption of Pancera et al.16 The authors stated that the
mechanism of action ofmebendazolemay be due to unspecific
immunomodulation.
Chatterjee and Van Marck17 explored the possible mod-
ulatory role of the neuropeptide somatostatin in the outcome
of Schistosoma morbidity in man. The authors stated that
somatostatin has an inhibitory effect on hormone, immune,
and physiological body functions, like growth hormone, inter-
feron gamma production, collagen I and III formation, and
hepatic stellate cell activation. Therefore, somatostatin may
determine pre-disposition to ‘‘Schistosoma’’ morbidity in
man.17
More recently, Doenhoff et al.,18 stated that aqueous
extracts of Schistosoma mansoni eggs have been shown to
have fibrinolytic activity inhibitable by a serine protease
inhibitor. Last but not least, Pyrrho et al.19 investigated the
possible use of immunomodulators as coadjuvants in the treat-
ment of chronic Schistosoma mansoni infection. The authors
evaluated the effect of dexamethasone in chronic experimen-
tal schistosomiasis. They found that the drug induced a
decrease in the number of hepatic granulomata without
affecting the alanine aminotransferase profile. It also reduced
splenomegaly and hepatomegaly associated with the disease
and improved hemoglobin concentration, hematocrit values,
and reduced the percentage of reticulocytes, preventing the
development of anemia that occurs in the chronic phase of the
infection. These data suggest that treatmentwith dexametha-
sone results in a mild course of murine schistosomiasis and
point to this drug as a promising agent to complement Schis-
tosoma mansoni-specific treatment.19
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